Skip to Content

Join the 'HIV Infection' group to help and get support from people like you.

HIV Infection News

Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS

High HIV Rates for Gay Men in Some Southern Cities

Posted 8 days ago by Drugs.com

WEDNESDAY, May 18, 2016 – Rates of HIV infection among gay and bisexual men are approaching 30 percent to 40 percent in some southern U.S. cities, a new report finds. According to the study, about 39.5 percent of gay and bisexual men in Jackson, Miss., are now HIV-positive, as are about 29 percent of gay/bisexual men living in El Paso, Texas, or Columbia, S.C. Other southern cities – Augusta, Ga., Baton Rouge, La., Little Rock, Ark. – also have rates of HIV infection for gay and bisexual men around 25 percent, the report found. Of the 25 U.S. metropolitan areas with the highest rates, 21 were in southern states, the researchers said. Their analysis of 2012 data identified six states where more than 15 percent of gay/bisexual men had HIV, and all of those states were in the South. Overall, about 15 percent of gay/bisexual men in the United States have HIV, the virus that causes AIDS, ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis

HIV Patients Less Likely to Get Treatment for Cancer: Study

Posted 9 days ago by Drugs.com

TUESDAY, May 17, 2016 – While powerful HIV medications are granting longer lives to many people infected with the virus, a new U.S. study shows these same patients are less likely to get treatment for cancer if it develops. It's not clear why the difference exists. It could reflect the decisions of physicians, patients or both. Whatever the case, the finding confirms that the gap persists even when patients have private insurance or are otherwise healthy, the study authors said. Previous research has suggested that "people with well-controlled HIV infection should be treated similarly to patients without HIV," said study author Dr. Gita Suneja. However, "even looking at cancer patients with private health insurance only, we saw that those with HIV infection were less likely to receive cancer treatment for many common cancer types," said Suneja. She is an assistant professor of ... Read more

Related support groups: Cancer, Methotrexate, HIV Infection, Fluorouracil, Lung Cancer, Xeloda, Hydroxyurea, Mercaptopurine, Hydrea, Carboplatin, Cisplatin, Temodar, Cytoxan, Dacogen, Gemzar, Cyclophosphamide, Bendamustine, Treanda, Oxaliplatin, Capecitabine

HIV Decline Falls Short of U.S. 5-Year Goal

Posted 20 days ago by Drugs.com

FRIDAY, May 6, 2016 – Although HIV infection and transmission rates in the United States declined over the past five years, they fell short of White House targets, a new study finds. Between 2010 and 2015, new HIV infections decreased 11 percent and transmission of the AIDS-causing virus declined 17 percent, far less than the goals set in 2010 as part of the U.S. National HIV/AIDS Strategy (NHAS), researchers said. The NHAS goals for 2015 were reductions of 25 percent for new HIV infections and 30 percent declines in HIV transmission. "Even though we missed the goals by a sizable margin, it's promising to see that we made important progress in reducing rates of HIV infection and transmission," said lead study author Robert Bonacci. He is a fourth-year medical student at the University of Pennsylvania Perelman School of Medicine. The aim was to lower the persistent HIV infection rate ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Kaletra, Tenofovir, Viread, Norvir, Telaprevir, Entecavir, Viekira Pak, Nevirapine, Reyataz

Antibody Shot Protects Monkeys From HIV-Like Infection

Posted 27 Apr 2016 by Drugs.com

WEDNESDAY, April 27, 2016 – A single injection of a powerful HIV-fighting antibody protected monkeys from an HIV-like infection for up to six months, scientists report. Researchers from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) found that each of four HIV antibodies helped protect macaque monkeys from repeated exposure to a modified version of HIV, although some of the antibodies protected the animals longer than others. Experts said the findings, published April 28 in the journal Nature, represent progress in a new approach to eventually creating an HIV vaccine. Scientists have worked for decades toward the goal of having an HIV vaccine, with little success. In 2009, a clinical study known as the "Thai trial" produced the first vaccine to offer some protection against HIV, the virus that causes AIDS, but it only lessened transmission by a modest degree. ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Diagnosis and Investigation, Vaccination and Prophlaxis

People With HIV May Age Faster, Study Suggests

Posted 21 Apr 2016 by Drugs.com

THURSDAY, April 21, 2016 – People with HIV may age prematurely, putting them at increased risk for an earlier death, a new study indicates. With antiretroviral therapy, many people with HIV can expect to live for decades after being infected with the AIDS-causing virus. However, doctors have noted that these patients often show signs of premature aging. Using what they called a highly accurate marker for aging on a biological level, the study authors reported that HIV seems to cause an average of nearly five years of premature aging. This increases the risk of early death by 19 percent, according to the study published April 21 in the journal Molecular Cell. "The medical issues in treating people with HIV have changed," said study co-author Howard Fox, a professor in the department of pharmacology and experimental neuroscience at the University of Nebraska Medical Center in Omaha. ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Kaletra, Viread, Tenofovir, Norvir, Telaprevir, Entecavir, Lamivudine, Reyataz, Nevirapine, Boceprevir, Lexiva, Norvir Soft Gelatin, Hepsera, Ritonavir, Epivir

HIV Patients Now Living Long Enough to Develop Alzheimer's

Posted 19 Apr 2016 by Drugs.com

TUESDAY, April 19, 2016 – The first case of Alzheimer's disease diagnosed in a person with HIV highlights the fact that long-time HIV survivors are starting to reach ages where their risk for Alzheimer's increases, researchers report. The 71-year-old man was diagnosed after a medical scan revealed amyloid protein clumps in his brain. Until now, it was believed that HIV-related inflammation in the brain might prevent the formation of such clumps and thereby protect these people from Alzheimer's. "This patient may be a sentinel case that disputes what we thought we knew about dementia in HIV-positive individuals," said study author Dr. R. Scott Turner. He is head of the Memory Disorders Program at Georgetown University Medical Center in Washington, D.C. The case also suggests that some older people with HIV and dementia may be misdiagnosed with HIV-associated brain disorders, but ... Read more

Related support groups: HIV Infection, Dementia, Alzheimer's Disease, Pre-Exposure Prophylaxis, Mild Cognitive Impairment, Arteriosclerotic Dementia, Lewy Body Dementia, Arteriosclerotic Dementia w/ Depressive Features

FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy

Posted 5 Apr 2016 by Drugs.com

FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. Descovy is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. Descovy has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis, and post treatment acute exacerbation of hepatitis B. See below for important safety information. TAF is a novel targeted prodrug of tenofovir that has demonstrated high antiviral ... Read more

Related support groups: HIV Infection, Truvada, Tenofovir, Descovy, Emtricitabine/Tenofovir, Emtricitabine/tenofovir Alafenamide, Emtricitabine

Doctors Report Groundbreaking HIV-to-HIV Organ Transplants

Posted 31 Mar 2016 by Drugs.com

WEDNESDAY, March 30, 2016 – Trailblazing liver and kidney transplants from an HIV-positive donor to HIV-positive recipients were announced Wednesday by surgeons at Johns Hopkins University. "A couple of weeks ago, we performed the first HIV-to-HIV liver transplant in the world and the first HIV-to-HIV kidney transplant in the United States," Dr. Dorry Segev said during a midday media briefing. Before 2013 and passage of the HIV Organ Policy Equity Act, this kind of medical advance would not have been possible, because it was illegal for HIV-positive patients to donate organs in the United States. The act allows HIV-positive donors to donate organs to patients infected with the AIDS-causing virus, Segev said. Until the law was changed, thousands of patients with HIV in need of organ transplants often risked death while waiting for a donated organ, he said. At the same time, "we were ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Organ Transplant - Rejection Prophylaxis, Organ Transplant, Graft-versus-host disease, Rejection Prophylaxis

Work With Monkeys May Benefit HIV Babies

Posted 22 Mar 2016 by Drugs.com

TUESDAY, March 22, 2016 – Treating baby monkeys within 24 hours of exposure to an HIV-like virus eliminated the virus, a new study says. The findings suggest that giving antibodies to human infants infected with HIV by their mothers might clear the AIDS-causing virus from their bodies, according to the researchers. "We knew going into this study that HIV infection spreads very quickly in infants during mother-to-child transmission," said study senior author Nancy Haigwood, director of the Oregon National Primate Research Center at Oregon Health & Science University. "So we knew that we had to treat the infant rhesus macaques quickly but we were not convinced an antibody treatment could completely clear the virus after exposure. We were proven wrong," she said in a university news release. The study was published March 21 in the journal Nature Medicine. Rates of mother-to-child HIV ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Diagnosis and Investigation

FDA Approves Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the Treatment of HIV-1 Infection

Posted 8 Mar 2016 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 1, 2016-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single tablet regimen for the treatment of HIV. Odefsey is indicated as a complete regimen for the treatment of HIV-1 infection in patients 12 years of age and older who have no antiretroviral treatment history and HIV-1 RNA levels less than or equal to 100,000 copies per mL. O ... Read more

Related support groups: HIV Infection, Complera, Odefsey, Emtricitabine/rilpivirine/tenofovir, Emtricitabine/rilpivirine/tenofovir Alafenamide

In Monkeys, Therapy Flushes HIV-Like Virus From Its Hiding Places

Posted 26 Feb 2016 by Drugs.com

FRIDAY, Feb. 26, 2016 – One of the key roadblocks to a cure for HIV infection and AIDS is the fact that the virus can "hide out" in a dormant state in immune system cells, evading treatment. However, research in monkeys suggests that a new approach might push these hidden cells out of hiding, to where they can be destroyed by conventional antiretroviral drug therapy [ART]. The finding would need to be replicated in people, and many animal studies don't pan out in humans. Still, the research team from Emory University in Atlanta believes the therapy might some day "effectively diminish [the] HIV reservoir under ART as a means to establish a functional cure." The findings were presented Thursday at the annual Conference on Retroviruses and Opportunistic Infections in Boston. Experts note that research presented at medical meetings is typically considered preliminary until published in a ... Read more

Related support groups: HIV Infection

Half of Gay Black Men May Become Infected With HIV, CDC Says

Posted 23 Feb 2016 by Drugs.com

TUESDAY, Feb. 23, 2016 – If current HIV rates continue, about half of gay and bisexual black men in the United States will be diagnosed with the AIDS-causing virus in their lifetime, a new government analysis says. Gay and bisexual Hispanic males – another population group at serious risk of HIV – have a one in four chance of contracting HIV, according to the report from the U.S. Centers for Disease Control and Prevention. "As alarming as these lifetime risk estimates are, they are not a foregone conclusion. They are a call to action," said Dr. Jonathan Mermin, director of the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and Tuberculosis Prevention. "The prevention and care strategies we have at our disposal today provide a promising outlook for future reductions of HIV infections and disparities in the U.S., but hundreds of thousands of people will be diagnosed in their ... Read more

Related support groups: Opiate Dependence, HIV Infection, Drug Dependence, Pre-Exposure Prophylaxis, Toxic Reactions Incl Drug and Substance Abuse

Prenatal Use of HIV Drug May Slow Child's Development Slightly

Posted 23 Feb 2016 by Drugs.com

TUESDAY, Feb. 23, 2016 – A drug used to prevent mother-to-child HIV transmission during pregnancy may slow language development slightly in children, a new study suggests. Researchers followed more than 900 infants who were born to HIV-positive mothers but were not infected by the AIDS-causing virus. All of the mothers took antiretroviral drugs during pregnancy. Some of the treatment regimens included a drug called atazanavir (Reyataz), while others did not. The infants underwent a standard test of development at 1 year of age. The 167 infants whose mothers took atazanavir during pregnancy had slightly lower language and social development scores than the 750 infants whose mothers did not take the drug. But the study only showed an association between atazanavir and language delays in children, and did not prove a cause-and-effect link. And the difference in social development scores ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Kaletra, Tenofovir, Viread, Norvir, Telaprevir, Entecavir, Viekira Pak, Nevirapine, Reyataz

Vaginal Ring Offers Some Protection Against HIV, Study Says

Posted 23 Feb 2016 by Drugs.com

MONDAY, Feb. 22, 2016 – An insertable vaginal ring containing a month's supply of a continuous-release HIV prevention drug reduced the risk of HIV in African women by at least 27 percent, a new study found. The ring works by slowly and continuously delivering a highly localized and controlled amount of the antiretroviral medication dapivirine. This drug aims to halt the ability of HIV – the virus that causes AIDS – to replicate inside a healthy cell. The goal: to prevent HIV infection, rather than treat it, the researchers said. "These results come after a number of challenging years in the effort to find ways to improve HIV control," said study lead author Dr. Jared Baeten, a professor in the departments of global health, medicine and epidemiology at the University of Washington in Seattle. "But while the dapivirine vaginal ring isn't commercially available yet, I'm really very ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Viral Infection, Kaletra, Tenofovir, Viread, Norvir, Entecavir, Viekira Pak, Telaprevir, Genvoya

Alcohol More Harmful for People With HIV, Study Suggests

Posted 9 Feb 2016 by Drugs.com

MONDAY, Feb. 8, 2016 – Drinking alcohol may be more dangerous for people infected with HIV, a new study suggests. The effects of alcohol appear to be more pronounced for those with the virus that causes AIDS, even when the virus is suppressed with modern antiretroviral treatment (ART), the Yale University researchers reported. They noted that HIV patients who have just one or two drinks a day are at greater risk for death or alcohol-related health issues. The study involved patients treated by the U.S. Department of Veterans Affairs between 2008 and 2012. There were more than 18,000 HIV-positive patients and over 42,000 people not infected with the virus. The researchers investigated the link between drinking alcohol, death and other health issues the patients developed. They found the patients with HIV who drank even moderate amounts of alcohol were more likely to develop ... Read more

Related support groups: HIV Infection, Alcohol Dependence, Tamiflu, Pre-Exposure Prophylaxis, Incivek, Alcoholism, Hangover, Baraclude, Victrelis, Kaletra, Oseltamivir, Tenofovir, Viread, Norvir, Telaprevir, Entecavir, Boceprevir, Nevirapine, Lamivudine, Reyataz

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Pre-Exposure Prophylaxis, Viral Infection

Related Drug Support Groups

Atripla, Truvada, Stribild, Complera, Triumeq, Kaletra, Viread, tenofovir, Norvir, view more... nevirapine, Reyataz, lamivudine, Genvoya, Privigen, ritonavir, Norvir Soft Gelatin, Tivicay, immune globulin intravenous, Combivir, Sandoglobulin, Prezista, abacavir, Epivir, Lexiva, Epzicom, Intelence, Trizivir, Sustiva, Carimune, dolutegravir, didanosine, indinavir, efavirenz, Prezcobix, Odefsey, nelfinavir, darunavir, Ziagen, lamivudine / zidovudine, atazanavir, Fuzeon, Agenerase, stavudine, Edurant, amprenavir, zidovudine, Retrovir, abacavir / dolutegravir / lamivudine, Isentress, Descovy, raltegravir, Telzir, Carimune NF, Venoglobulin-S 10%, Dutrebis, Gammagard S / D, Evotaz, Selzentry, Venoglobulin-S 5%, Gamimune N 10%, Zerit XR, Octagam, Panglobulin NF, Gamimune, Gammar IV, Gammaplex, Iveegam En, Panglobulin, Vitekta, Tybost, Polygam S / D, Gamimune N 5%, Viramune XR, Gammar-P IV, Crixivan, etravirine, zalcitabine, tipranavir, saquinavir, emtricitabine / lopinavir / ritonavir / tenofovir, emtricitabine / nelfinavir / tenofovir, cobicistat / elvitegravir / emtricitabine / tenofovir, emtricitabine / rilpivirine / tenofovir, rilpivirine, maraviroc, lopinavir / ritonavir, delavirdine, abacavir / lamivudine / zidovudine, abacavir / lamivudine, efavirenz / emtricitabine / tenofovir, emtricitabine, fosamprenavir, enfuvirtide, emtricitabine / tenofovir, elvitegravir, cobicistat, Viramune, Viracept, Epivir-HBV, Fortovase, Invirase, Hivid, Aptivus, Zerit, Emtriva, Videx EC, lamivudine / raltegravir, cobicistat / darunavir, atazanavir / cobicistat, cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide, emtricitabine / rilpivirine / tenofovir alafenamide, Videx, Rescriptor, emtricitabine / tenofovir alafenamide, Flebogamma